AQST — Aquestive Therapeutics Share News
0.000.00%
Last trade - 00:00- $507.07m
- $549.32m
- $44.55m
Brief: Aquestive Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Aquestive Therapeutics Announces Pivotal Study For Anaphylm
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria's Secret & Co
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria'S Secret & Co
Aquestive Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aquestive Therapeutics Reports Full Year 2023 Financial Results
Aquestive Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
Brief: Aquestive Therapeutics, Inc. Q3 revenue USD 13.002 million
Aquestive Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Aquestive Therapeutics Completes $45 Mln Debt Refinancing
Aquestive Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Aquestive Therapeutics Anticipates Increasing 2023 Revenue
Brief: Aquestive Therapeutics Inc Files For Resale Of Up To 2.75 Million Shares Of Common Stock By The Selling Stockholder
Brief: Aquestive Therapeutics Receives FDA Acceptance Of New Drug Application (NDA) For Libervant
Aquestive Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aquestive Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Aquestive Therapeutics Reports Positive Results From Latest Clinical Studies Evaluating Pharmacokinetic And Pharmacodynamic Performance Of Anaphylm ™ (Epinephrine) Sublingual Film And Provides Findings From Recent Auto-Injector Clinical Study
Aquestive Therapeutics Inc reports results for the quarter ended in March - Earnings Summary